73 filings
8-K
UBX
Unity Biotechnology Inc
14 May 24
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results
5:00pm
8-K
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
UBX
Unity Biotechnology Inc
20 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:15pm
8-K
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
7:00am
8-K
dkbhy2n7xkk61p0d1idb
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
r0limgjjljp
6 Sep 23
Termination of a Material Definitive Agreement
4:05pm
8-K
evygb
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
yzmjqcxz359b
23 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
znr6o4
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K/A
vvy2preo55 kx4m
28 Apr 23
Departure of Directors or Certain Officers
4:05pm
8-K
zjpk4cwi6g1y1a 9u7
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
l3bjtw q9
11 Apr 23
Departure of Directors or Certain Officers
4:06pm
8-K
hb596r62yvgnyfl
27 Mar 23
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:00am
8-K
ywwyy03ljc2j
17 Mar 23
Other Events
5:14pm
8-K
371hox92
15 Mar 23
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
4:25pm
8-K
wi32m stx
10 Mar 23
Regulation FD Disclosure
8:00pm
8-K
ndd6k3nisoo5nt4zhqjd
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
u8wedhio
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
58yn0lr
19 Oct 22
Material Modifications to Rights of Security Holders
5:06pm